Adaptive has partnered with Microsoft to map and decode the human immune system. Specialized cells of the adaptive immune system, T and B cells, constantly respond to infections and cancer. These same cells are also involved in different autoimmune disorders. By reading  and decoding the adaptive immune system, we aim to translate into the clinic the natural capability of the immune system to recognize and fight disease.

We use the exquisite specificity of T-cell receptors (TCRs) to discover and validate T-cell signatures of disease—from infectious diseases to autoimmune conditions and in the future, potentially to cancer. We do this by building a map that links trillions of TCRs with millions of disease antigens. Our goal is to make the diagnosis and monitoring of disease more accurate and reliable.

By combining our proprietary immunosequencing technology, computational modeling, and machine learning capabilities, we are making significant advances in how we can better detect and treat disease. Our drug discovery capabilities allow us to discover and fully characterize immune receptors—TCRs and antibodies—to develop as therapeutic products.